3/19
09:16 am
dnth
Dianthus Therapeutics (DNTH) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $135.00 price target on the stock.
Low
Report
Dianthus Therapeutics (DNTH) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $135.00 price target on the stock.
3/18
05:19 pm
dnth
Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP [Yahoo! Finance]
Low
Report
Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP [Yahoo! Finance]
3/18
02:27 pm
dnth
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit [Yahoo! Finance]
Low
Report
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit [Yahoo! Finance]
3/16
12:08 pm
dnth
Dianthus Therapeutics (DNTH) had its "outperform" rating reaffirmed by William Blair.
Low
Report
Dianthus Therapeutics (DNTH) had its "outperform" rating reaffirmed by William Blair.
3/15
08:58 am
dnth
Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm [Yahoo! Finance]
Low
Report
Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm [Yahoo! Finance]
3/12
08:44 pm
dnth
Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision [Yahoo! Finance]
Medium
Report
Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision [Yahoo! Finance]
3/12
04:01 pm
dnth
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
3/11
02:58 am
dnth
Dianthus Therapeutics prices upsized $625M public offering at $81/share [Seeking Alpha]
Low
Report
Dianthus Therapeutics prices upsized $625M public offering at $81/share [Seeking Alpha]
3/10
10:54 pm
dnth
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
Low
Report
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
3/10
02:13 pm
dnth
Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating [Seeking Alpha]
Low
Report
Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating [Seeking Alpha]
3/10
08:35 am
dnth
Dianthus Therapeutics (DNTH) was upgraded by Raymond James Financial, Inc. from "outperform" to "strong-buy". They now have a $123.00 price target on the stock, up from $63.00.
High
Report
Dianthus Therapeutics (DNTH) was upgraded by Raymond James Financial, Inc. from "outperform" to "strong-buy". They now have a $123.00 price target on the stock, up from $63.00.
3/10
08:35 am
dnth
Dianthus Therapeutics (DNTH) had its price target raised by Wedbush from $55.00 to $80.00. They now have an "outperform" rating on the stock.
High
Report
Dianthus Therapeutics (DNTH) had its price target raised by Wedbush from $55.00 to $80.00. They now have an "outperform" rating on the stock.
3/10
08:10 am
dnth
Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) [Yahoo! Finance]
High
Report
Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) [Yahoo! Finance]
3/10
08:03 am
dnth
Dianthus Therapeutics (DNTH) had its price target raised by Robert W. Baird from $67.00 to $132.00. They now have an "outperform" rating on the stock.
High
Report
Dianthus Therapeutics (DNTH) had its price target raised by Robert W. Baird from $67.00 to $132.00. They now have an "outperform" rating on the stock.
3/9
08:55 pm
dnth
Dianthus Therapeutics, Inc. (DNTH) Discusses Interim Responder Analysis and Early Go Decision for CAPTIVATE Trial in CIDP Transcript [Seeking Alpha]
High
Report
Dianthus Therapeutics, Inc. (DNTH) Discusses Interim Responder Analysis and Early Go Decision for CAPTIVATE Trial in CIDP Transcript [Seeking Alpha]
3/9
06:05 pm
dnth
Dianthus Therapeutics (DNTH) was given a new $98.00 price target by Jefferies Financial Group Inc.. They now have a "buy" rating on the stock.
High
Report
Dianthus Therapeutics (DNTH) was given a new $98.00 price target by Jefferies Financial Group Inc.. They now have a "buy" rating on the stock.
3/9
04:01 pm
dnth
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
High
Report
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
3/9
01:51 pm
dnth
Dianthus Therapeutics (DNTH) had its price target raised by HC Wainwright from $47.00 to $130.00. They now have a "buy" rating on the stock.
Low
Report
Dianthus Therapeutics (DNTH) had its price target raised by HC Wainwright from $47.00 to $130.00. They now have a "buy" rating on the stock.
3/9
01:06 pm
dnth
Dianthus Therapeutics (DNTH) had its "buy" rating reaffirmed by TD Cowen.
Low
Report
Dianthus Therapeutics (DNTH) had its "buy" rating reaffirmed by TD Cowen.
3/9
01:06 pm
dnth
Dianthus Therapeutics (DNTH) was given a new $120.00 price target by Stifel Nicolaus.
Low
Report
Dianthus Therapeutics (DNTH) was given a new $120.00 price target by Stifel Nicolaus.
3/9
12:06 pm
dnth
Dianthus Therapeutics (DNTH) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
Medium
Report
Dianthus Therapeutics (DNTH) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
3/9
10:22 am
dnth
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
Low
Report
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
3/9
08:43 am
dnth
Dianthus Therapeutics (DNTH) had its price target raised by Truist Financial Corporation from $63.00 to $110.00. They now have a "buy" rating on the stock.
Low
Report
Dianthus Therapeutics (DNTH) had its price target raised by Truist Financial Corporation from $63.00 to $110.00. They now have a "buy" rating on the stock.
3/9
07:32 am
dnth
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Yahoo! Finance]
Low
Report
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Yahoo! Finance]
3/9
07:23 am
dnth
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results [Yahoo! Finance]
Low
Report
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results [Yahoo! Finance]